Hot Investor Mandate: Corporate VC Arm of Global Pharmaceutical Company Invests in Breakthrough Therapeutic Platform Technologies Across the Globe

8 Sep

A corporate venture arm of a global pharmaceutical company. The firm seeks to make strategic investments into early-stage companies that are aligned with the firm’s R&D focus. For equity investments, the firm will lead, co-lead, or participate in syndicated financings.

The firm’s core focus is therapeutic platform technologies. The firm specifically targets investment opportunities that fall within the parent company’s therapeutic areas of interest: Oncology, Gastrointestinal Diseases, Neuro (non-behavioral), Rare Disease, and more. The firm is primarily interested in breakthrough platforms and is generally modality agnostic. The firm does not invest in single therapeutic assets, medical devices or diagnostics.

The firm focuses on early stage investments (Seed and Series A) in pre-clinical, therapeutic platforms. The firm invests using standard institutional venture investment terms without special rights or options.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Global Company’s Corporate Venture Arm Invests Broadly Across Diverse Life Science Sectors, With a Focus on USA-Based Companies

8 Sep

The corporate venture arm of a global company makes seed, venture and growth stage investments in companies in the life sciences space as well as other spaces like IT and mobility. The firm typically makes equity investments in the range of $3-5M per portfolio company. The firm primarily invests in life science companies based in the US, but due to the firm’s global presence, the firm can also invest in companies based in Asia. The firm has no current mandate for the number of allocations it plans to make in the space and will evaluate relevant opportunities as they surface.

The firm invests in early-stage companies in the biotech therapeutics, medical technology and devices, diagnostics, and healthcare IT sectors. The firm is sector and indication agnostic, and is opportunistic regarding company stage of development.

The firm is looking for companies with a strong and qualified management team or technical experts in the relevant technology. The firm can act as either a lead or co-investor.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Arm of Global Supply & Manufacturing Company Seeks to Invest and Partner With Device & Diagnostics Companies and Life Science Tools

8 Sep

The venture capital arm of a global supplier of building materials as well as a manufacturer of innovative material solutions. The firm is looking for companies that will align with the parent company’s strategy for either equity investments, partnerships, licensing or acquisition. Within the life sciences, the firm will consider medical devices, novel materials, diagnostics, instruments and tools. The firm is willing to invest globally, and will invest as early as prototype/proof-of-concept stage.

Within the life sciences, the firm is interested in medical device, diagnostic or instrument and tool companies. The firm will consider all medical devices, but, if FDA approval is required, the firm prefers the company to be in the approval process. For diagnostics, the firm will consider both diagnostic/monitoring machines, tools, instruments & novel materials for Genomics & Cell & Gene therapies. The firm is also interested in instruments or tools that can be used in the medical field or for research purposes.

The firm can lead or co-invest in equity investing, and their involvement in the company after investment will depend on the partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based VC Firm Invests in Early-Stage Technologies from Seed to Series A, Most Interested in Intersection of Life Science and Technology

8 Sep

A venture capital firm based in the USA is focused on investing in early-stage companies at the intersection of life sciences and technology, with an emphasis on neuroscience. The firm is interested in enabling technologies, biotech platforms, pharma tools, digital health, and health IT related to this area, and is currently looking to either lead or co-invest as part of a syndicate. The firm plans to invest in Seed and Series A rounds, with companies with proof-of-concept data. The firm will make $0.25-2M initial investments, and is currently focused on the US.

The firm will invest in therapeutic platforms, pharma tools, services, health IT, and digital health companies that are related to neuroscience and other related therapeutic areas including oncology, autoimmune and inflammatory disorders.

The firm is currently looking to lead or co-invest, and may take a board or observer seat, depending on the deal size, portfolio priorities, and operational needs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

RESI Returns this Month

1 Sep

By Rory McCann, Director of Marketing & Conference Producer, LSN

After a more-than-two-year hiatus, RESI Boston returns to an in-person format September 21-22 at the Westin Copley Place Hotel with an additional day for virtual partnering, September 23. In a recent conversation with Life Science Nation CEO, Dennis Ford, we discussed how RESI has evolved over the past few years, and also the features that make RESI unique and consistently powerful in early-stage life science and healthcare partnering, regardless of event format. We also discussed some new faces at RESI Boston and how we are celebrating our return to RESI’s hometown of Boston, MA. Check out our interview below and sign up to start booking meetings today!

RESI-Boston-2022-Banner-with-lilly-logo-1100px

RESI Boston IPC Finalists

1 Sep

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claireThe RESI Boston, September 21-23, Innovator’s Pitch Challenge (IPC) finalists are in! The IPC will include 14 sessions for finalist companies to pitch to a judging panel featuring investors and strategic partners. In addition, each company will be presenting a posterboard in the RESI exhibit hall throughout the conference. All RESI attendees will be given 5 pieces of “RESI Cash,” which can be used to “invest” or vote for their favorite companies, and the Top 3 companies with the highest number of votes will be announced at the end of RESI with a prize and newsletter feature.

Participating in the IPC is an unparalleled opportunity for actively fundraising startups to boost their exposure and engage a wider network of global investors and strategic partners.

See all pitching companies:

Interested in learning more about these companies? The RESI partnering system just opened on Monday – it is not too late to register for RESI and engage with IPC finalists and 700+ attendees who will be attending RESI. Sign up here!

RESI-Boston-2022-Banner-with-lilly-logo-1100px

RESI Boston Partnering Now Open

1 Sep

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Partnering has launched for RESI Boston, September 21-23! Even in a few short days, the system has been buzzing with activity that proves the need for early-stage deals is as high as ever. More than 700 attendees are expected to take part in the 3-day hybrid RESI event, with two days of in-person partnering and one day of virtual partnering. This format allows for attendees to take advantage of the options to book meetings with fellow registrants, regardless of partnering style.

There is still plenty of time to register and connect – make sure to take advantage of this opportunity to book meetings with investors and strategic partners who are a fit for you, regardless of location. RESI is a truly global event, and we invite you to check out the upcoming partnering tutorial to learn more about the RESI system and how to make it work for you.

Partnering Tutorial – September 6, Tuesday – Sign Up

RESI-Boston-2022-Banner-with-lilly-logo-1100px

← Older Entries
Newer Entries →